期刊文献+

蛋白质及多肽类药物长效化研究进展 被引量:6

Progress in research on techniques for prolonging half-life of protein and polypeptide drugs
原文传递
导出
摘要 随着分子生物学技术和基因重组技术的发展,蛋白质与多肽类药物凭借其独特的优势已逐渐成为一种重要的临床药物类型;但稳定性差,半衰期短的缺点也极大限制了其在临床上的广泛应用。本文针对目前延长蛋白质和多肽类药物半衰期的具体方法及其注意事项进行了综述。 Following the advancement in molecular biology and recombinant technology, the protein and polypeptide thera-peutics have become an important class of clinical drugs due to their unique superiority. However, the problems of stability and short half-life of proteins and peptides also vastly limit their further use in clinic. The focal points of this paper are to introduce the specific ways and the matters needing attention to increase the biological half-life of the therapeutic protein and polypeptide drugs.
出处 《中国血吸虫病防治杂志》 CAS CSCD 2012年第5期594-597,共4页 Chinese Journal of Schistosomiasis Control
基金 国家自然科学基金(30972581) 江苏省自然科学基金(BK2008110)
关键词 药理学 蛋白质 多肽 半衰期 免疫原性 Pharmacology Protein Polypeptide Half-life Immunogenicity
  • 相关文献

参考文献28

  • 1Pisal DS, Kosloski MP, Baluiyer SV. Delivery of therapeutic proteins [J]. J Pharm Sci, 2010, 99(6) :2557-2575.
  • 2迈博姆.生物技术药物药代动力学与药效动力学-药物开发指导原则与应用实例[M].程远国,译.北京:人民军医出版社,2010:22-26.
  • 3Sinclair AM, Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins [J]. J Pharm Sci, 2005, 94 (8) : 1626-1635.
  • 4Ceaglio N, Etcheverrigaray M, K-r atje R, et al. Influence of carbohy- drates onthe stability and structure of a hyperglycosylated human in- terferon alpha mutein[J]. Biochimistry, 2010, 92(8) : 971-978.
  • 5Richards AA, Colgrave ML, Zhang JL, et al. Sialic acid modification of adipo-nectin is not required for multimerization or secretion but de- termines half-lifein circulation [J]. Mol Endocrinol, 2010, 24 (1) : 229-239.
  • 6Werner RG, Kopp K, Schlueter M. Glycosylation of therapeutic pro- teins in different production systems [J]. Acta Paediatrica Suppl, 2007, 96(455) : 17-22.
  • 7Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conju- gates and nanoparticles[J]. J Contro Release, 2008, 132 (3) :171 - 183.
  • 8Chuang VT, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin [J]. Pharm Res, 2002, 19(5) :569-576.
  • 9Muller N, Schneider B, Pfizenma-ier K, et al. Superior serum half life of albumin tagged TNF ligands [J~. Biochem Biophys Res Com- mun, 2010, 396(4):793-799.
  • 10Gao Z, Bai G, Chen J, et al.-Development, characterization and evaluation of a fusion protein of a novel glucagon like peptide- 1 (GLP-1) analog and human serum albumin in Pichia pastoris [J]. Biosci Bioteehnol Biochem, 2009,73 (3) : 688-694.

二级参考文献19

  • 1郑彩虹,梁文权,虞和永.海藻酸壳聚糖聚乳酸羟乙醇酸复合微球的制备及其对蛋白释放的调节[J].药学学报,2005,40(2):182-186. 被引量:20
  • 2Seki T,Kawaguchi T,Endoh H,et al.Controlled release of 3',5'-diester prodrugs of 5-fluoro-2'-deoxyuridine from poly-L-lactic acid microspheres[J].J Pharm Sci,1990,79 (11):985-987.
  • 3Diwan M,Park TG.Pegylation enhances protein stability during encapsulation in PLGA microspheres[J].J Controlled Release,2001,73 (2-3):233-244.
  • 4O'Hagan DT,Jeffery H,Davis SS.The preparation and characterization of poly (lactide-co-glycolide) microparticles:Ⅲ.Microparticle/polymer degradation rates and the in vitro release of a model protein[J].Int J Pharm,1994,103 (1):37-45.
  • 5Raman C,Berkland C,Kim K,et al.Modeling small-molecule release from PLG microspheres:effects of polymer degradation and nonuniform drug distribution[J].J Controlled Release,2005,103(1):149-158.
  • 6Matsumoto A,Matsukawa Y,Suzuki T,et al.Drug release characteristics of multi-reservoir type microspheres with poly (dl-lactide-co-glycolide) and poly (dl-lactide)[J].J Controlled Release,2005,106 (1-2):172-180.
  • 7Rojas J,Pinto-Alphandary H,Leo E,et al.A Polysorbate-based nonionic surfactant can modulate loading and release of β-lactoglobulin entrapped in multiphase poly (DL-lactide-coglycolide) microspheres[J].Pharm Res,1999,16 (2):255-260.
  • 8Wang J,Wang BM,Schwendeman SP.Mechanistic evaluation of the glucose-induced reduction in initial burst release of octreotide acetate from poly (D,L-lactide-co-glycolide)microspheres[J].Biomaterials,2004,25 (10):1919-1927.
  • 9Takada S,Kurokawa T,Miyazaki K,et al.Utilization of an amorphous form of a water-soluble GPⅡb/Ⅲa antagonist for controlled release from biodegradable microspheres[J].Pharm Res,1997,14(9):1146-1150.
  • 10Lam XM,Duenas ET,Cleland JL.Encapsulation and stabilization of nerve growth factor into poly (lactic-co-glycolic)acid microspheres[J].J Pharm Sci,2001,90 (9):1356-1365.

共引文献6

同被引文献57

引证文献6

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部